Safety and Efficacy of Sodium Pentaborate Pentahydrate in People With Overweight and Obesity

Evaluation of the Safety and Efficacy and of Sodium Pentaborate Pentahydrate in People With Overweight and Obesity: a Randomized, Double-blind, Placebo-controlled Phase 1/2 Trial

This study investigates the safety and efficacy of sodium pentaborate pentahydrate in improving the body weight and glycemic profile of patients with overweight or obesity compared to the placebo group.

Study Overview

• Status: Not yet recruiting
• Conditions: Overweight and Obesity
• Intervention / Treatment: Drug: Placebo; Drug: Sodium pentaborate pentahydrate

Detailed Description

Obesity is considered one of the pandemics of the current century which is associated with great mortality and morbidity. In addition to changing diet and physical activity, medicines, devices, and even surgery are suggested for obesity. Although they can be effective partially, however, the rate of recurrence is high and some are invasive. So, there is a need to evaluate other types of potential interventions for obesity management. Due to the effects of boron-derivates in the prevention and management of obesity, we will evaluate the safety and efficacy of sodium pentaborate pentahydrate in patients with overweight and obesity in terms of its safety and efficacy. This study will be conducted as a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, phase 1/2 trial. Individuals aged ≥18 years with body mass index (BMI) ≥30.0 kg/m2 or BMI ≥27.0 kg/m2 with the presence of hypertension or dyslipidemia will be recruited. Participants will be randomly assigned (6:1) to oral administration of once-daily sodium pentaborate pentahydrate (200, 400, 600, 800, 1000 mg), or placebo, using balanced block randomization. The primary endpoint will be the relative change from baseline in body weight (%) at 12 weeks. Adverse events will be monitored and checked closely in terms of physical examinations and laboratory measures.

• Study Type: Interventional
• Enrollment (Anticipated): 120
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Saeid Safiri, PhD; Phone Number: +984133342178; Email: saeidsafiri@gmail.com

Study Locations

• Iran, Islamic Republic of
  • East Azarbayejan
    • Tabriz, East Azarbayejan, Iran, Islamic Republic of, 5166614766
      • Imam Reza hospital and clinic of Salamat

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age ≥18 years at the time of signing the informed consent.
• A non-pregnant female participant or a male participant who has been surgically sterilized (vasectomy) or is willing to use appropriate contraceptive methods during the trial (until the end of the trial).
• Body mass index (BMI) ≥30·0 kg/m2 or BMI ≥27·0 kg/m2 in the presence of hypertension or dyslipidemia (treated or untreated, assessed at the discretion of the investigator).

Exclusion Criteria:

• Glycosylated hemoglobin (HbA1c) ≥48 mmol/mol (6.5%) as measured by the laboratory at screening.
• History of type 1 or type 2 diabetes.
• Treatment with glucose-lowering drug(s) within 90 days prior to screening.
• Obesity caused by endocrine disorders (such as Cushing's syndrome)
• Change in body weight of more than 5 kg during the 90 days before screening regardless of medical records.
• Treatment with any drug proven to control weight in the 90 days before screening.
• Previous or planned obesity treatment (during the trial period) with surgery or a weight loss device. However, the following are permitted: (1) liposuction and/or abdominoplasty, if performed more than one year prior to screening; (2) lap banding, if the banding was removed more than 1 year before the screening. (3) intragastric balloon, if the balloon was removed more than 1 year before the screening. or (4) duodenal-jejunal bypass sleeve, if the sleeve was removed more than 1 year before the screening.
• Uncontrolled thyroid disease, defined as TSH >4·78 mIU/L or 1.5 times the upper limit of normal as measured by a laboratory at screening.
• Inadequately treated hypertension, defined at screening as systolic ≥180 mmHg or diastolic ≥110 mmHg.
• History of malignant neoplasms in the last 5 years before the screening. Basal and squamous cell skin cancer and any in situ cancer are allowed.
• Presence or history of cardiovascular disease, including stable and unstable angina pectoris, myocardial infarction, transient ischemic attack, stroke, cardiac decompensation, clinically significant arrhythmias, or clinically significant conduction disturbances.
• The participant is currently classified as having New York Heart Association Class IV heart failure.
• Surgery planned during the trial period, excluding minor surgery, at the discretion of the investigator.
• Known or suspected abuse of alcohol or recreational drugs.
• Known or suspected hypersensitivity to test product(s) or related products.
• Participation in another clinical trial within 90 days prior to screening.
• Personal or first-degree relative history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
• Presence of acute pancreatitis within 180 days before screening.
• History or presence of chronic pancreatitis.
• Any impairment, unwillingness, or disability, not covered by any of the other exclusion criteria, that in the opinion of the investigator may compromise the participant's safety or compliance with the protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Capsules containing sodium pentaborate pentahydrate 200 mg; Capsules containing sodium pentaborate pentahydrate 200 mg orally once a day	Drug: Sodium pentaborate pentahydrate; Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg
Active Comparator: Capsules containing sodium pentaborate pentahydrate 400 mg; Capsules containing sodium pentaborate pentahydrate 400 mg orally once a day	Drug: Sodium pentaborate pentahydrate; Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg
Active Comparator: Capsules containing sodium pentaborate pentahydrate 600 mg; Capsules containing sodium pentaborate pentahydrate 600 mg orally once a day	Drug: Sodium pentaborate pentahydrate; Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg
Active Comparator: Capsules containing sodium pentaborate pentahydrate 800 mg; Capsules containing sodium pentaborate pentahydrate 800 mg orally once a day	Drug: Sodium pentaborate pentahydrate; Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg
Active Comparator: Capsules containing sodium pentaborate pentahydrate 1000 mg; Capsules containing sodium pentaborate pentahydrate 1000 mg orally once a day	Drug: Sodium pentaborate pentahydrate; Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg
Placebo Comparator: Placebo capsules; Placebo capsules of the same shape, smell, and color orally once a day	Drug: Placebo; Placebo capsules; Other Names: Placebo capsules

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of body weight	The relative change of body weight compared to the base weight (%)	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Weight loss ≥ 5% of initial body weight	Proportion (%) of people with weight loss ≥ 5% of initial body weight	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Weight loss ≥ 10% of initial body weight	Proportion (%) of people with weight loss ≥ 10% of initial body weight	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Change in waist circumference	Relative change in waist circumference compared to baseline	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Change in body mass index	Relative change in body mass index compared to baseline	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Change of waist to hip circumference	Relative change of waist to hip circumference compared to baseline	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Hemoglobin A1c level	Change in hemoglobin A1c level	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Fasting blood glucose	Change in fasting blood glucose levels	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Insulin level	Change in insulin level	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Systolic and diastolic blood pressures	Changes in systolic and diastolic blood pressures	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
High density lipoprotein (HDL) levels	Changes in high density lipoprotein (HDL) levels	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Low density lipoprotein (LDL) levels	Changes in low density lipoprotein (LDL) levels	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Triglyceride levels	Changes in triglyceride levels	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Total cholesterol levels	Changes in total cholesterol levels	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
High-sensitivity C-reactive protein levels	Changes in high-sensitivity C-reactive protein levels	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Adverse events	Registration of adverse events in questionnaires	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Short-Form 36 (SF-36) v2·0 acute score	Changes in Short-Form 36 (SF-36) v2·0 acute scores. It ranges zero to 100 and lower scores mean higher disability.	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16
Three-Factor Eating Questionnaire Revised 18-item version 2 score (TFEQ-R18v2)	Changes in Three-Factor Eating Questionnaire Revised 18-item version 2 score (TFEQ-R18v2). It has four-point response scales ranging from definitely true (score = 4) to definitely false (score = 1).	Screening, randomization and weeks 2, 4, 6, 8, 10, 12, 16

Collaborators and Investigators

• Sponsor: Tabriz University of Medical Sciences
• Investigators: Principal Investigator: Saeid Safiri, PhD, Tabriz University of Medical Sciences

Study record dates

Study Major Dates

• Study Start (Anticipated): July 21, 2023
• Primary Completion (Anticipated): March 20, 2024
• Study Completion (Anticipated): March 21, 2025

Study Registration Dates

• First Submitted: February 13, 2023
• First Submitted That Met QC Criteria: February 13, 2023
• First Posted (Actual): February 23, 2023

Study Record Updates

• Last Update Posted (Actual): April 14, 2023
• Last Update Submitted That Met QC Criteria: April 11, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: Obesity; Overweight; Sodium pentaborate pentahydrate
• Additional Relevant MeSH Terms: Overnutrition; Nutrition Disorders; Body Weight; Obesity; Overweight
• Other Study ID Numbers: 70928

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No